HC Wainwright & Co. Maintains Buy on Mirum Pharmaceuticals, Raises Price Target to $66
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has maintained a Buy rating on Mirum Pharmaceuticals (NASDAQ:MIRM) and raised the price target from $58 to $66.
June 17, 2024 | 5:03 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. has maintained a Buy rating on Mirum Pharmaceuticals and raised the price target from $58 to $66.
The raised price target and maintained Buy rating from a reputable analyst firm like HC Wainwright & Co. is likely to positively impact investor sentiment and drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100